Kite Pharma, Inc. - Product Pipeline Review – 2015 Is Released Kite Pharma, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct s, Kite Pharma, Inc. Product Pipeline Review - 2015, provides an overview of the Kite Pharma, Inc. s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Kite Pharma, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Kite Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Kite Pharma, Inc.s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Kite Pharma, Inc.s pipeline products Reasons to buy - Evaluate Kite Pharma, Inc.s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Kite Pharma, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Kite Pharma, Inc. s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Kite Pharma, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kite Pharma, Inc. - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Kite Pharma, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues 1
Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179155/kite-pharma-inc-product-pipeline-review-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179155/kite-pharma-inc-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Kite Pharma, Inc. Snapshot 5 Kite Pharma, Inc. Overview 5 Key Information 5 Key Facts 5 Kite Pharma, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Kite Pharma, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Kite Pharma, Inc. - Pipeline Products Glance 11 Kite Pharma, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Kite Pharma, Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Kite Pharma, Inc. - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14
2
Kite Pharma, Inc. - Drug Profiles 15 Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 KTEC-19 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Cellular Immunotherapy to Target EGFR vIII for Glioblastoma, Brain Cancer, Head and neck cancer 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cellular Immunotherapy to Target MAGE A3 for Oncology 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Cellular Immunotherapy to Target MAGE A3 and A6 for Oncology 26 Product Description 26 Mechanism of Action 26 3
R&D Progress 26 Cellular Immunotherapy for Hematological Malignancies and Solid Tumors 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Cellular Immunotherapy to Target SSX2 for Solid Tumor 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Kite Pharma, Inc. - Pipeline Analysis 31 Kite Pharma, Inc. - Pipeline Products by Target 31 Kite Pharma, Inc. - Pipeline Products by Route of Administration 32 Kite Pharma, Inc. - Pipeline Products by Molecule Type 33 Kite Pharma, Inc. - Pipeline Products by Mechanism of Action 34 Kite Pharma, Inc. - Recent Pipeline Updates 35 Kite Pharma, Inc. - Dormant Projects 41 Kite Pharma, Inc. - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 4
Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Kite Pharma, Inc. Snapshot 5 Kite Pharma, Inc. Overview 5 Key Information 5 Key Facts 5 Kite Pharma, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Kite Pharma, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Kite Pharma, Inc. - Pipeline Products Glance 11 Kite Pharma, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 5
Kite Pharma, Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Kite Pharma, Inc. - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14 Kite Pharma, Inc. - Drug Profiles 15 Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 KTEC-19 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Cellular Immunotherapy to Target EGFR vIII for Glioblastoma, Brain Cancer, Head and neck cancer 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cellular Immunotherapy to Target MAGE A3 for Oncology 24 Product Description 24 6
Mechanism of Action 24 R&D Progress 24 Cellular Immunotherapy to Target MAGE A3 and A6 for Oncology 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Cellular Immunotherapy for Hematological Malignancies and Solid Tumors 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Cellular Immunotherapy to Target SSX2 for Solid Tumor 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Kite Pharma, Inc. - Pipeline Analysis 31 Kite Pharma, Inc. - Pipeline Products by Target 31 Kite Pharma, Inc. - Pipeline Products by Route of Administration 32 Kite Pharma, Inc. - Pipeline Products by Molecule Type 33 Kite Pharma, Inc. - Pipeline Products by Mechanism of Action 34 Kite Pharma, Inc. - Recent Pipeline Updates 35 7
Kite Pharma, Inc. - Dormant Projects 41 Kite Pharma, Inc. - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44 Read More http://www.idatainsights.com/reports-landing-page.php?id=179155/kite-pharma-incproduct-pipeline-review-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship
8
with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
9